![]() | |
Clinical data | |
---|---|
Trade names | Angiocept |
Other names | CT-322; BMS-844203 |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C468H729N125O139S (un- PEGylated peptide) |
Molar mass | 10362.78 g·mol−1 |
Pegdinetanib ( USAN; planned trade name Angiocept) is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), hindering vascularization of tumors. It is a genetically engineered peptide derivative based on the monobody technology, and is being developed by Adnexus. [1] [2]
The drug has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007. [3] [4] As of August 2012 [update], it is also in Phase II trials for the treatment of non-small cell lung cancer [5] and colorectal cancer. [6]
Pegdinetanib is a peptide consisting of 94 amino acids, with cysteine number 93 carrying a doubly methoxy- PEGylated maleimide derivative with a molecular mass of 40 kDa. [7]
![]() | |
Clinical data | |
---|---|
Trade names | Angiocept |
Other names | CT-322; BMS-844203 |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C468H729N125O139S (un- PEGylated peptide) |
Molar mass | 10362.78 g·mol−1 |
Pegdinetanib ( USAN; planned trade name Angiocept) is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), hindering vascularization of tumors. It is a genetically engineered peptide derivative based on the monobody technology, and is being developed by Adnexus. [1] [2]
The drug has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007. [3] [4] As of August 2012 [update], it is also in Phase II trials for the treatment of non-small cell lung cancer [5] and colorectal cancer. [6]
Pegdinetanib is a peptide consisting of 94 amino acids, with cysteine number 93 carrying a doubly methoxy- PEGylated maleimide derivative with a molecular mass of 40 kDa. [7]